FARMINGDALE, N.Y., June 1, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ:MSON - News), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications has announced a new five-year exclusive U.S. distribution agreement with Anika Therapeutics S.r.l., a wholly owned subsidiary of Anika Therapeutics, Inc. (NASDAQ:ANIK - News), a leader in products for tissue protection, healing, and repair. Misonix will sell and distribute Anika's HyalomatrixR product, a skin substitute based on hyaluronic acid technology. ?Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds and will be a companion product for Misonix's SonicOneR Ultrasonic Wound Cleansing and Debridement System.
Anika will manufacture and supply finished product to Misonix, while Misonix will be responsible for all aspects of commercialization in the United States. ?A recognized leader in advanced ultrasonic wound management, Misonix has U.S. sales and marketing organizations for both the surgery and clinic settings, where acute and chronic wounds are treated. ?Both sales organizations will market the Hyalomatrix product offering.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. ?The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to expand its presence in the rapidly growing advanced wound care market by undertaking the U.S. distribution of another state-of-the-art wound care product," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Anika's Hyalomatrix skin substitute will hold an important position in our treatment protocol for advanced wound management and is synergistic to our own SonicOne product line.
"This Agreement demonstrates the Company's continued commitment to growth in large markets either by organic growth or the distribution of synergistic world class products through our domestic sales forces. ?The addition of Hyalomatrix is consistent with our plan to leverage the value of our existing distribution organization by adding more high value products to our sales pipeline."
About Misonix: ?Misonix, Inc. (NASDAQ:MSON - News) designs, manufactures and markets therapeutic ultrasonic medical devices. ?Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. ?Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. ?Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. ?These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. ?Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, ?regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. ?The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com
